Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

rena previously settled in June 2006 a similar disagreement with the other warrant holder.

Cash, cash equivalents and short-term investments totaled $272.2 million at June 30, 2008. Approximately 73.9 million shares of common stock were outstanding at June 30, 2008.

Arena's Recent and Second Quarter Highlights

-- Completed BLOSSOM enrollment with 4,008 obese and overweight patients in about 95 clinical sites in the United States. BLOSSOM is a one-year, randomized, double-blind, placebo-controlled clinical trial. BLOSSOM and BLOOM comprise Arena's pivotal trial program evaluating lorcaserin's safety and efficacy for the treatment of obesity.

-- Reported positive Phase 1b clinical trial results of APD791, Arena's internally discovered oral drug candidate intended for the treatment of arterial thrombosis and other related conditions. This Phase 1b trial was a randomized, double-blind, placebo-controlled multiple-ascending dose trial in 50 healthy volunteers.

-- Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment of insomnia in an oral presentation at the SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies. When compared to placebo, APD125 significantly improved endpoints measuring improvements in sleep maintenance without any next day impairment of cognition or coordination.

-- Initiated a Phase 2b clinical trial of APD125, Arena's internally discovered oral drug candidate intended to reduce insomnia symptoms and improve sleep maintenance and quality. This is a randomized, double-blind, placebo-controlled subjective study that is expected to enroll approximately 675 patients in about 65 clinical sites in the United States.

-- Taisho Pharmaceutical Co., Ltd. initiated a Phase 1 clinical trial of a drug candidate under a GPCR-focused partnership to develop compounds to treat psychiatric disorders. The drug candidate is a n
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... MA (PRWEB) May 19, 2013 The ... social media training online, has proudly announced that the ... small business has surpassed 175,000 views on YouTube. The ... social media and SEO tips and training for small ... my students find the YouTube tips helpful for their ...
(Date:5/17/2013)... recipient,s immune system identifies the transplanted organ as foreign ... T cells, the immune cells that mediate rejection, must ... order to migrate to the transplanted organ. In this ... Fadi Lakkis and colleagues at the University of Pittsburgh ... cells is not required for migration. Instead, these cells ...
(Date:5/17/2013)... 2013 •    First of its kind research ... ,     New facility will help solve crop stresses ... Syngenta unveiled its new crop research facility during ... Innovation Center. The first of its kind, $72 million ... agricultural climate and precisely measure plant inputs – the ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to ... Switzerland -based Kenta Biotech to ... antibody (mAb) products, and technologies. This asset portfolio ... treatment of infections by common pathogens including drug ... Pseudomonas aeruginosa , Acinetobacter baumannii ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... Inc. (NASDAQ: OPTR ) today announced that ... Suisse Healthcare Conference on Thursday, November 10 at 10:00 ... (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A live audio ... Investors page of the Company,s website at www.optimerpharma.com ...
... Elsevier, a world-leading provider of scientific, ... the availability of Elsevier Urban & Fischer Journal ... and health sciences, on SciVerse ScienceDirect . ... renowned German imprint Urban & Fischer, contain journals concerning ...
... ON Engineering researchers at the University of Toronto ... (OLEDs) on plastic. This result enables a flexible form ... traditional OLED manufacturing, which currently relies on rigid glass. ... latest issue of Nature Photonics . OLEDs ...
Cached Biology Technology:Elsevier Announces Availability of Urban & Fischer Journal Archives on SciVerse ScienceDirect 2University of Toronto researchers create world's most efficient flexible OLED on plastic 2
(Date:5/16/2013)... a conservationist working in Cameroon and the manager of ... been awarded the prestigious Whitley award. The Whitley ... "The Green Oscars" because it celebrates the extraordinary achievements ... developing countries. Abwe was selected for the award ... Cameroon,s Ebo Forest and its wildlife inhabitants., HRH The ...
(Date:5/16/2013)... , May 16, 2013 Reportlinker.com ... is available in its catalogue: ... Opportunities, 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... old security practises such as photographs, passwords ... of biometric technologies in last few years. ...
(Date:5/15/2013)... in moderating gout risk, new research reveals that vitamin ... acid (urate) levels to a clinically significant degree in ... in combination with allopurinol, appears to have a weak ... according to the results published in the American College ... , Gout is an inflammatory arthritis that causes ...
Breaking Biology News(10 mins):Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2
... International, an independent nonprofit research and development organization, ... was selected by the National Cancer Institute (NCI) ... Biology Consortium" (CBC), a collaborative drug discovery partnership ... novel molecular and genetic cancer targets. Based on ...
... Institute have for the first time produced a malarial ... generate a significant immune response in mice and non-human ... induced by Pfs48/45 protein vaccine effectively blocked the sexual ... it grows within the mosquito. Sexual development is a ...
... 2009 Berry research is currently attracting significant applied, ... need for a rigorously peer-reviewed publication in this area, ... the Journal of Berry Research . According ... Politecnica della Marche, Department of Biochemistry, Biology & Genetics, ...
Cached Biology News:SRI announces selection by the National Cancer Institute as a Chemical Biology Consortium center 2Vaccine blocks malaria transmission in lab experiments 2IOS Press announces launch of Journal of Berry Research 2IOS Press announces launch of Journal of Berry Research 3
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Request Info...
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Biology Products: